1
|
Hillyer A, Quint A, Ghassemian A, Joh-Carnella N, Knauer MJ, Dawd D, Lazo-Langner A, Mangel J, Lam S, Abdoh H, Xenocostas A, Deotare U, Saini L, Foster C, Louzada M, Ho J, Chin-Yee I, Phua CW. Serologic Response to Vaccine for COVID-19 in Patients with Hematologic Malignancy: A Prospective Cohort Study. Clin Lymphoma Myeloma Leuk 2024:S2152-2650(24)00021-1. [PMID: 38336492 DOI: 10.1016/j.clml.2024.01.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/12/2023] [Revised: 01/04/2024] [Accepted: 01/06/2024] [Indexed: 02/12/2024]
Abstract
BACKGROUND Patients with hematological cancers have increased COVID-19 morbidity and mortality, and these patients show attenuated vaccine responses. This study aimed to characterize the longitudinal humoral immune responses to COVID-19 vaccination in patients with hematological malignancies. PATIENTS AND METHODS We conducted a prospective cohort study, collecting samples from March 2021 to July 2022, from patients seen at a cancer treatment center in London, Ontario, Canada, who met the following eligibility criteria: age ≥18 years, diagnosed with a hematological malignancy, recipient of a COVID-19 vaccine during the study period, and able to provide informed consent. RESULTS Median anti-S titers (MST) were 0.0, 64.0, and 680.5 U/mL following first (V1), second (V2), and third (V3) vaccine doses, respectively. Patients with lymphoid malignancies' response to vaccination was attenuated compared to myeloid malignancy patients after V2 and V3 (P < .001, P < .01). Active treatment was associated with lower antibody titers (MST 10) compared to treatment 12-24 months (MST 465, P = .04367) and >24 months (MST 1660.5, P = .0025) prior to vaccination. V3 significantly increased antibody titers compared to V2 for patients less than 3 months from treatment. Increasing age was associated with smaller antibody response following V2 (P < .05), but not following V3. Patients receiving anti-CD20 therapy did not demonstrate increased antibody titer levels after V3 (V2 MST 0, V3 MST 0; P > .05). CONCLUSION We report an attenuated serologic response to COVID-19 vaccination in our study population of patients with hematological malignancy. The immune response to vaccination was affected by patient age, diagnosis, treatment, and timing of treatment exposure.
Collapse
Affiliation(s)
| | | | - Artin Ghassemian
- Division of Hematology and Department of Pathology and Laboratory Medicine, London Health Sciences Centre, London, ON
| | | | - Michael J Knauer
- Department of Pathology and Laboratory Medicine, London Health Sciences Centre, London, ON
| | - Danny Dawd
- Schulich School of Medicine and Dentistry, Western University, London ON
| | - Alejandro Lazo-Langner
- Division of Hematology and Department of Pathology and Laboratory Medicine, London Health Sciences Centre, London, ON
| | - Joy Mangel
- Division of Hematology and Department of Pathology and Laboratory Medicine, London Health Sciences Centre, London, ON
| | - Selay Lam
- Division of Hematology and Department of Pathology and Laboratory Medicine, London Health Sciences Centre, London, ON
| | - Husam Abdoh
- Department of Pathology and Laboratory Medicine, London Health Sciences Centre, London, ON
| | - Anargyros Xenocostas
- Division of Hematology and Department of Pathology and Laboratory Medicine, London Health Sciences Centre, London, ON
| | - Uday Deotare
- Division of Hematology and Department of Pathology and Laboratory Medicine, London Health Sciences Centre, London, ON
| | - Lalit Saini
- Division of Hematology and Department of Pathology and Laboratory Medicine, London Health Sciences Centre, London, ON
| | - Cheryl Foster
- Division of Hematology and Department of Pathology and Laboratory Medicine, London Health Sciences Centre, London, ON
| | - Martha Louzada
- Division of Hematology and Department of Pathology and Laboratory Medicine, London Health Sciences Centre, London, ON
| | - Jenny Ho
- Division of Hematology and Department of Pathology and Laboratory Medicine, London Health Sciences Centre, London, ON
| | - Ian Chin-Yee
- Division of Hematology and Department of Pathology and Laboratory Medicine, London Health Sciences Centre, London, ON
| | - Chai W Phua
- Division of Hematology and Department of Pathology and Laboratory Medicine, London Health Sciences Centre, London, ON.
| |
Collapse
|
2
|
Chinnadurai A, Strum S, Ghassemian A, Fortin D, Foster C, Breadner D. A Rare Association of Mixed Autoimmune Hemolytic Anemia with Gastric Carcinoma. Case Rep Oncol 2023; 16:1209-1216. [PMID: 37900792 PMCID: PMC10601801 DOI: 10.1159/000534278] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2023] [Accepted: 09/21/2023] [Indexed: 10/31/2023] Open
Abstract
This case report outlines a 70-year-old female patient who presented with a concurrent mixed autoimmune hemolytic anemia (AIHA) and a gastric adenocarcinoma. Her treatment course of these two diseases is summarized, which included supportive care, neoadjuvant chemotherapy for her gastric adenocarcinoma, steroids, rituximab, and surgical resection of the tumor. This approach ultimately led to the stabilization of her AIHA and primary cure for her solid malignancy. We briefly review both AIHA and gastric adenocarcinoma as clinical entities, propose working causes of hemolytic anemia including gastric adenocarcinoma, and outline a successful treatment pathway for these two concurrent conditions.
Collapse
Affiliation(s)
- Anu Chinnadurai
- Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada
| | - Scott Strum
- Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada
- London Regional Cancer Program, London Health Sciences Centre, Victoria Hospital, London, ON, Canada
| | - Artin Ghassemian
- Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada
- London Regional Cancer Program, London Health Sciences Centre, Victoria Hospital, London, ON, Canada
| | - Dalilah Fortin
- Department of Surgery, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada
| | - Cheryl Foster
- Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada
- London Regional Cancer Program, London Health Sciences Centre, Victoria Hospital, London, ON, Canada
| | - Daniel Breadner
- Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada
- London Regional Cancer Program, London Health Sciences Centre, Victoria Hospital, London, ON, Canada
| |
Collapse
|
3
|
Llona-Minguez S, Höglund A, Ghassemian A, Desroses M, Calderón-Montaño JM, Burgos Morón E, Valerie NCK, Wiita E, Almlöf I, Koolmeister T, Mateus A, Cazares-Körner C, Sanjiv K, Homan E, Loseva O, Baranczewski P, Darabi M, Mehdizadeh A, Fayezi S, Jemth AS, Warpman Berglund U, Sigmundsson K, Lundbäck T, Jenmalm Jensen A, Artursson P, Scobie M, Helleday T. Correction to Piperazin-1-ylpyridazine Derivatives Are a Novel Class of Human dCTP Pyrophosphatase 1 Inhibitors. J Med Chem 2017; 60:7614. [DOI: 10.1021/acs.jmedchem.7b01137] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
4
|
Llona-Minguez S, Höglund A, Ghassemian A, Desroses M, Calderón-Montaño JM, Burgos Morón E, Valerie NCK, Wiita E, Almlöf I, Koolmeister T, Mateus A, Cazares-Körner C, Sanjiv K, Homan E, Loseva O, Baranczewski P, Darabi M, Mehdizadeh A, Fayezi S, Jemth AS, Warpman Berglund U, Sigmundsson K, Lundbäck T, Jenmalm Jensen A, Artursson P, Scobie M, Helleday T. Piperazin-1-ylpyridazine Derivatives Are a Novel Class of Human dCTP Pyrophosphatase 1 Inhibitors. J Med Chem 2017; 60:4279-4292. [DOI: 10.1021/acs.jmedchem.7b00182] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Affiliation(s)
- Sabin Llona-Minguez
- Division
of Translational Medicine and Chemical Biology, Science for Life Laboratory,
Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm 171 65, Sweden
| | - Andreas Höglund
- Division
of Translational Medicine and Chemical Biology, Science for Life Laboratory,
Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm 171 65, Sweden
| | - Artin Ghassemian
- Division
of Translational Medicine and Chemical Biology, Science for Life Laboratory,
Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm 171 65, Sweden
| | - Matthieu Desroses
- Division
of Translational Medicine and Chemical Biology, Science for Life Laboratory,
Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm 171 65, Sweden
| | - José Manuel Calderón-Montaño
- Division
of Translational Medicine and Chemical Biology, Science for Life Laboratory,
Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm 171 65, Sweden
| | - Estefanía Burgos Morón
- Division
of Translational Medicine and Chemical Biology, Science for Life Laboratory,
Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm 171 65, Sweden
| | - Nicholas C. K. Valerie
- Division
of Translational Medicine and Chemical Biology, Science for Life Laboratory,
Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm 171 65, Sweden
| | - Elisee Wiita
- Division
of Translational Medicine and Chemical Biology, Science for Life Laboratory,
Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm 171 65, Sweden
| | - Ingrid Almlöf
- Division
of Translational Medicine and Chemical Biology, Science for Life Laboratory,
Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm 171 65, Sweden
| | - Tobias Koolmeister
- Division
of Translational Medicine and Chemical Biology, Science for Life Laboratory,
Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm 171 65, Sweden
| | - André Mateus
- Uppsala
University Drug Optimization and Pharmaceutical Profiling Platform
(UDOPP), Department of Pharmacy, Science for Life Laboratory, Uppsala University, Uppsala 752 37, Sweden
| | - Cindy Cazares-Körner
- Division
of Translational Medicine and Chemical Biology, Science for Life Laboratory,
Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm 171 65, Sweden
| | - Kumar Sanjiv
- Division
of Translational Medicine and Chemical Biology, Science for Life Laboratory,
Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm 171 65, Sweden
| | - Evert Homan
- Division
of Translational Medicine and Chemical Biology, Science for Life Laboratory,
Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm 171 65, Sweden
| | - Olga Loseva
- Division
of Translational Medicine and Chemical Biology, Science for Life Laboratory,
Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm 171 65, Sweden
| | - Pawel Baranczewski
- Uppsala
University Drug Optimization and Pharmaceutical Profiling Platform
(UDOPP), Department of Pharmacy, Science for Life Laboratory, Uppsala University, Uppsala 752 37, Sweden
| | - Masoud Darabi
- Department
of Biochemistry and Clinical Laboratories, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz 5165665931, Iran
| | - Amir Mehdizadeh
- Department
of Biochemistry and Clinical Laboratories, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz 5165665931, Iran
| | - Shabnam Fayezi
- Department
of Biology and Anatomical Sciences, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran 1983969411, Iran
| | - Ann-Sofie Jemth
- Division
of Translational Medicine and Chemical Biology, Science for Life Laboratory,
Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm 171 65, Sweden
| | - Ulrika Warpman Berglund
- Division
of Translational Medicine and Chemical Biology, Science for Life Laboratory,
Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm 171 65, Sweden
| | - Kristmundur Sigmundsson
- Division
of Translational Medicine and Chemical Biology, Science for Life Laboratory,
Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm 171 65, Sweden
- Chemical
Biology Consortium Sweden, Science for Life Laboratory, Division of
Translational Medicine and Chemical Biology, Department of Medical
Biochemistry and Biophysics, Karolinska Institutet, Stockholm 171 65, Sweden
| | - Thomas Lundbäck
- Division
of Translational Medicine and Chemical Biology, Science for Life Laboratory,
Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm 171 65, Sweden
- Chemical
Biology Consortium Sweden, Science for Life Laboratory, Division of
Translational Medicine and Chemical Biology, Department of Medical
Biochemistry and Biophysics, Karolinska Institutet, Stockholm 171 65, Sweden
| | - Annika Jenmalm Jensen
- Division
of Translational Medicine and Chemical Biology, Science for Life Laboratory,
Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm 171 65, Sweden
- Chemical
Biology Consortium Sweden, Science for Life Laboratory, Division of
Translational Medicine and Chemical Biology, Department of Medical
Biochemistry and Biophysics, Karolinska Institutet, Stockholm 171 65, Sweden
| | - Per Artursson
- Uppsala
University Drug Optimization and Pharmaceutical Profiling Platform
(UDOPP), Department of Pharmacy, Science for Life Laboratory, Uppsala University, Uppsala 752 37, Sweden
| | - Martin Scobie
- Division
of Translational Medicine and Chemical Biology, Science for Life Laboratory,
Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm 171 65, Sweden
| | - Thomas Helleday
- Division
of Translational Medicine and Chemical Biology, Science for Life Laboratory,
Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm 171 65, Sweden
| |
Collapse
|